Cargando…

Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations

OBJECTIVE: To compare the cost-effectiveness of 2 possible screening strategies for gestational diabetes mellitus (GDM) from the perspective of the New Zealand health system, developed as part of a gestational diabetes guideline. DESIGN: A decision analytic model was built comparing 2-step screening...

Descripción completa

Detalles Bibliográficos
Autores principales: Coop, Catherine, Edlin, Richard, Brown, Julie, Farquhar, Cindy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480026/
https://www.ncbi.nlm.nih.gov/pubmed/26100024
http://dx.doi.org/10.1136/bmjopen-2014-006996
_version_ 1782378109852450816
author Coop, Catherine
Edlin, Richard
Brown, Julie
Farquhar, Cindy
author_facet Coop, Catherine
Edlin, Richard
Brown, Julie
Farquhar, Cindy
author_sort Coop, Catherine
collection PubMed
description OBJECTIVE: To compare the cost-effectiveness of 2 possible screening strategies for gestational diabetes mellitus (GDM) from the perspective of the New Zealand health system, developed as part of a gestational diabetes guideline. DESIGN: A decision analytic model was built comparing 2-step screening (glycated haemoglobin (HbA1c) test at first booking and a 2 h 75 g oral glucose tolerance test (OGTT) as a single test at 24–28 weeks) with 3-step screening (HbA1c test at first booking and a 1 h glucose challenge test (GCT) followed by a 2 h 75 g OGTT when indicated from 24–28 weeks) using a 9-month time horizon. SETTING: A hypothetical cohort of 62 000 pregnant women in New Zealand. METHODS: Probabilities, costs and benefits were derived from the literature, and supplementary data was obtained from National Women's Annual Clinical Reports. Main outcome measures, screening and treatment costs (NZ$2013) and effect on health outcomes (incidence of complications). RESULTS: The total cost for both strategies under baseline assumptions shows that the 2-step screening strategy would cost NZ$1.38 m more than the 3-step screening strategy overall. The additional cost per case detected was NZ$12 460 per case. The model found that the 2-step screening strategy identifies 12 more women with diabetes and 111 more women with GDM when compared against the 3-step screening strategy. We assessed the effect of changing the sensitivity and specificity of the OGTT. The baseline model assumed that the 2 h 75 g OGTT has a sensitivity and specificity of 95%. The 2-step strategy becomes more cost-effective when the diagnostic accuracy measures are improved. CONCLUSIONS: Adopting a 2-step strategy would moderately increase the number of GDM cases detected at the same time as moderately increasing the number of women with false negatives at a significant cost to the health system. Further evidence on the benefits of the 2 different approaches would be welcome.
format Online
Article
Text
id pubmed-4480026
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-44800262015-07-02 Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations Coop, Catherine Edlin, Richard Brown, Julie Farquhar, Cindy BMJ Open Obstetrics and Gynaecology OBJECTIVE: To compare the cost-effectiveness of 2 possible screening strategies for gestational diabetes mellitus (GDM) from the perspective of the New Zealand health system, developed as part of a gestational diabetes guideline. DESIGN: A decision analytic model was built comparing 2-step screening (glycated haemoglobin (HbA1c) test at first booking and a 2 h 75 g oral glucose tolerance test (OGTT) as a single test at 24–28 weeks) with 3-step screening (HbA1c test at first booking and a 1 h glucose challenge test (GCT) followed by a 2 h 75 g OGTT when indicated from 24–28 weeks) using a 9-month time horizon. SETTING: A hypothetical cohort of 62 000 pregnant women in New Zealand. METHODS: Probabilities, costs and benefits were derived from the literature, and supplementary data was obtained from National Women's Annual Clinical Reports. Main outcome measures, screening and treatment costs (NZ$2013) and effect on health outcomes (incidence of complications). RESULTS: The total cost for both strategies under baseline assumptions shows that the 2-step screening strategy would cost NZ$1.38 m more than the 3-step screening strategy overall. The additional cost per case detected was NZ$12 460 per case. The model found that the 2-step screening strategy identifies 12 more women with diabetes and 111 more women with GDM when compared against the 3-step screening strategy. We assessed the effect of changing the sensitivity and specificity of the OGTT. The baseline model assumed that the 2 h 75 g OGTT has a sensitivity and specificity of 95%. The 2-step strategy becomes more cost-effective when the diagnostic accuracy measures are improved. CONCLUSIONS: Adopting a 2-step strategy would moderately increase the number of GDM cases detected at the same time as moderately increasing the number of women with false negatives at a significant cost to the health system. Further evidence on the benefits of the 2 different approaches would be welcome. BMJ Publishing Group 2015-06-22 /pmc/articles/PMC4480026/ /pubmed/26100024 http://dx.doi.org/10.1136/bmjopen-2014-006996 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Obstetrics and Gynaecology
Coop, Catherine
Edlin, Richard
Brown, Julie
Farquhar, Cindy
Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations
title Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations
title_full Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations
title_fullStr Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations
title_full_unstemmed Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations
title_short Cost-effectiveness of the New Zealand diabetes in pregnancy guideline screening recommendations
title_sort cost-effectiveness of the new zealand diabetes in pregnancy guideline screening recommendations
topic Obstetrics and Gynaecology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480026/
https://www.ncbi.nlm.nih.gov/pubmed/26100024
http://dx.doi.org/10.1136/bmjopen-2014-006996
work_keys_str_mv AT coopcatherine costeffectivenessofthenewzealanddiabetesinpregnancyguidelinescreeningrecommendations
AT edlinrichard costeffectivenessofthenewzealanddiabetesinpregnancyguidelinescreeningrecommendations
AT brownjulie costeffectivenessofthenewzealanddiabetesinpregnancyguidelinescreeningrecommendations
AT farquharcindy costeffectivenessofthenewzealanddiabetesinpregnancyguidelinescreeningrecommendations